Fig. 1 · Structure

Documents & Downloads

ML349

Cat. No. A12301 CAS 890819-86-0

APT-2 inhibitor

ML349 is a potent and specific acyl protein thioesterase 2 (APT-2) inhibitor with a Ki of 120 nM. ML349 is also an inhibitor of LYPLA2 with an IC50 of 144 nM.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
HEK-293T IC50 > 10 μM Inhibition of fluorescein-labeled ML349 binding to HEK293T cells-derived His-tagged PDXK expressed in Escherichia coli BL21(DE3) after 30 mins by fluorescence polarization assay [PMID: 28197315]
HEK-293T IC50 1.1 μM Inhibition of fluorescein-labeled ML349 binding to HEK293T cells-derived His-tagged APT2 expressed in Escherichia coli BL21(DE3) after 30 mins by fluorescence polarization assay [PMID: 28197315]

ML349 Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of ML349 from 3 published references. In vitro models include melanoma cells with NRAS mutations in exon II, exon III; BRAF mutant SK-MEL-28. In vivo models include MC1R RHC variant mice; C57BL/6 J female mice.

ML349 In Vitro Studies

ML349 was evaluated in NRAS-mutant melanoma cells and BRAF-mutant SK-MEL-28 cells, with DMSO-treated controls. Following incubation at <12.5 μM for 72hrs, ML349 did not decrease cell viability at the dosages used in either study. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cell viability in NRAS-mutant melanoma cells

Cell-based study · melanoma cells with NRAS mutations in exon II (NRAS G12), exon III (NRAS Q61) [1]

Melanoma cells with NRAS mutations were incubated with ML349 at <12.5 μM for 72hrs, with DMSO-treated controls. ML349 did not decrease cell viability at the dosages used.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viabilityReported result ML348 and ML349 do not decrease cell viability in melanoma cells at dosages used in this study.[1]

Literature-Reported Treatment Conditions

Treatment concentration
<12.5 μM
Exposure duration
incubation 72hrs
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: ML349

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Specific APT-1 and APT-2 inhibitors ML348 and ML349 do not affect cell viability in NRAS mutant melanoma cells (S14); Figure 3 legend (S64, S65)

cell viability: cell viability; comparator: DMSO treated controls — Figure 3 legend (S65)

Cell viability in BRAF-mutant melanoma cells

Cell-based study · BRAF mutant SK-MEL-28 [1]

BRAF-mutant SK-MEL-28 cells were incubated with ML349 at <12.5 μM for 72hrs, with DMSO-treated controls. ML349 did not decrease cell viability at the dosages used.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viabilityReported result ML348 and ML349 do not decrease cell viability in melanoma cells at dosages used in this study.[1]

Literature-Reported Treatment Conditions

Treatment concentration
<12.5 μM
Exposure duration
incubation 72hrs
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: ML349

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Specific APT-1 and APT-2 inhibitors ML348 and ML349 do not affect cell viability in NRAS mutant melanoma cells (S14, S15); Figure 3 legend (S64, S65)

cell viability: cell viability; comparator: DMSO treated controls — Figure 3 legend (S65)

ML349 In Vivo Studies

In MC1R RHC variant mice undergoing UVB irradiation, melanoma incidence was lower with ML349 treatment than without ML349 treatment. In C57BL/6 J female mice subsequently injected with N67 iRBCs, ML349 pretreatment significantly reduced parasitemia compared with DMSO. [2,3]

Melanoma incidence in MC1R RHC variant mice

Animal study · MC1R RHC variant mice (Tyr-Cre-BRAFCA/C57BL/6J-MC1Re/eJ/MC1RR151C-Tg) [2]

MC1R RHC variant mice received ML349 at 5 mg/kg intraperitoneally before UV treatment during the UVB radiation period. At 90 days after the final UVR, melanoma was diagnosed in 23% (3/13) of mice with ML349 treatment and 64% (7/11) without ML349 treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
melanoma incidencemelanoma incidence 23% (3/13) or 64% (7/11) of mice with or without ML349 treatment, respectively[2]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
In the UVB radiation period, 5 mg/kg ML349 was injected intraperitoneally into mice prior to the treatment with UV
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
ML349 5 mg/kgwithout ML349 treatment90 days after the final UVR, melanoma was diagnosed in 23% (3/13) or 64% (7/11) of mice with or without ML349 treatment, respectively (p = 0.0366; Fig. 4h)[2]
ML349 5 mg/kg
Model: MC1R RHC variant mice (Tyr-Cre-BRAFCA/C57BL/6J-MC1Re/eJ/MC1RR151C-Tg)
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: ML349

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Inhibition of APT2 inhibits UVB-induced melanomagenesis in vivo (S67, S68, S70); Methods > Animals (S89)

melanoma incidence: melanoma incidence; comparator: without ML349 treatment — Results > Inhibition of APT2 inhibits UVB-induced melanomagenesis in vivo (S67, S70)

ML349 5 mg/kg · Results > Inhibition of APT2 inhibits UVB-induced melanomagenesis in vivo (S68, S70)

Parasitemia following pretreatment in female mice

Animal study · C57BL/6 J female mice (n = 6 per group) [3]

C57BL/6 J female mice received ML349 at 5 mg/kg intraperitoneally for 7 days before injection of N67 iRBCs. ML349 pretreatment significantly reduced parasitemia compared with DMSO.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ParasitemiaReported result Pretreatment with ML349 significantly reduced parasitemia[3]

Conditions shared by the study groups

Route
intraperitoneally (i.p.)
Treatment course
for 7 days, followed by an injection of N67 iRBCs
Vehicle
DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
ML349 5 mg/kgDMSOPretreatment with ML349 significantly reduced parasitemia[3]
ML349 5 mg/kg
Model: C57BL/6 J female mice (n = 6 per group)
Methods and source locations

Compound reported in the paper: ML349

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > ML349 enhances mice resistance to N67 infection (S135); Fig. 7 legend (S428, S429)

Parasitemia: Parasitemia; comparator: DMSO — Results > ML349 enhances mice resistance to N67 infection (S135); Fig. 7 legend (S429)

ML349 5 mg/kg · Results > ML349 enhances mice resistance to N67 infection (S135); Fig. 7 legend (S428)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 890819-86-0
Applications APT-2 inhibitor
Formula C23H22N2O4S2
Molecular Weight 454.56
SMILES
COC1=CC=C(N2CCN(C(C3=CC4=C(C(C=CC=C5)=C5S(C4)(=O)=O)S3)=O)CC2)C=C1

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

ML349 Research References

  1. [1] Vujic I, Sanlorenzo M, Esteve-Puig R, et al. Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. Oncotarget (2016). PMID: 26771141 DOI: 10.18632/oncotarget.6907 Source material
  2. [2] Chen S, Han C, Miao X, et al. Targeting MC1R depalmitoylation to prevent melanomagenesis in redheads. Nat Commun (2019). PMID: 30787281 DOI: 10.1038/s41467-019-08691-3 Source material
  3. [3] Han Z, Xiong S, Zeng K, et al. Palmitoylation of TBK1 enhances the type I interferon signaling and strengthens anti-malarial immunity in mice. Nat Commun (2025). PMID: 41253837 DOI: 10.1038/s41467-025-65081-8 Source material

Added to your cart

View Cart Checkout
Loading...